CAJ | 학술논문

目的评价血管生成抑制剂沙利度胺联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应.方法 66例NSCLC随机分为治疗组和对照组.治疗组采用NP方案+沙利度胺治疗,长春瑞滨25～30 mg/m2,静滴,第1、8天;顺铂70～80 nc,/m2,静滴,第1天;沙利度胺200 mg/d,口服,第1天起连续给药.对照组采用NP方案化疗,剂量、方法与治疗组相同.结果治疗组和对照组的有效率分别为51.5%和36.4%,差异无统计学意义(P>0.05).治疗组和对照组的中位疾病进展时间(TTP)分别为6.0个月和3.6个月,治疗组的中位TTP显著延长(P=0.0005).治疗组和对照组间毒副反应发生率比较,差异无统计学意义(P>0.05);治疗组患者治疗后生活质量评分较对照组有提高,但差异无统计学意义(P>0.05).结论沙利度胺与NP方案具有协同作用,联合应用能显著提高晚期NSCLC患者的中位TTP,且不增加治疗后不良反应的发生率.
목적 평개혈관생성억제제사리도알연합화료치료만기비소세포폐암(NSCLC)적림상료효급불량반응.방법 66례NSCLC수궤분위치료조화대조조.치료조채용NP방안+사리도알치료,장춘서빈25～30 mg/m2,정적,제1、8천;순박70～80 nc,/m2,정적,제1천;사리도알200 mg/d,구복,제1천기련속급약.대조조채용NP방안화료,제량、방법여치료조상동.결과 치료조화대조조적유효솔분별위51.5%화36.4%,차이무통계학의의(P>0.05).치료조화대조조적중위질병진전시간(TTP)분별위6.0개월화3.6개월,치료조적중위TTP현저연장(P=0.0005).치료조화대조조간독부반응발생솔비교,차이무통계학의의(P>0.05);치료조환자치료후생활질량평분교대조조유제고,단차이무통계학의의(P>0.05).결론 사리도알여NP방안구유협동작용,연합응용능현저제고만기NSCLC환자적중위TTP,차불증가치료후불량반응적발생솔.
Objective To evaluate the efficacy, median time to progression (TIP), quality of life and toxicity in the patients with advanced non-small cell lung cancer(NSCLC), treated with thalidomide plus vinorelbine and cisplatin (NP) or NP alone. Methods Sixty six patients with advanced NSCLC were divided randomly into two groups, the trial and control groups. The trial group was treated with vinorelbine 25～30 mg/m2 I.v. On D1 and D8, cisplatin 70～80 mg/m2 I.v. On D1 (NP regimen), and thalidomise 200 nag orally and daily from D1. The control group received vinorelbine and eisplatin as above described. Results Of 66 assessable patients, the overall response rate was 51.5% in the trial group and 36.4% in the control group (P=0.22). The median TIP was 6.0 months for the trial group, and 3.6 months for the control group (P<0.001). The score of quality of life in trial group was higher than that in the control group, but no significant difference was observed between the two groups (P>0.05). There were no significant differences in toxicities between the two groups (P>0.05). Conclusion NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC. Thalidomide may have a synergie activity with NP regimen without increased toxicities.